- Home
- OCUL vs VRDN Comparison
OCUL vs VRDN Comparison
Compare OCUL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | VRDN |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | OCUL | VRDN |
|---|---|---|
| Price | $10.04 | $22.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $23.56 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,990,000.00 | ★ $5,706,000.00 |
| Revenue This Year | $7.93 | $13.73 |
| Revenue Next Year | $96.07 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.48 | N/A |
| 52 Week Low | $6.23 | $13.18 |
| 52 Week High | $16.44 | $34.29 |
Technical Indicators
Market Signals| Indicator | OCUL | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 62.73 |
| Support Level | $9.24 | $17.97 |
| Resistance Level | $9.93 | $34.18 |
| Average True Range (ATR) | 0.40 | 0.99 |
| MACD | 0.19 | 0.13 |
| Stochastic Oscillator | 76.54 | 67.40 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.